Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 5/20 | 0.44 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13741165 | 0.85 | MEN1 (0.45) | MEN1KMT2APOLBGAACTDSP1 | |
| SCHEMBL13713840 | 0.85 | MEN1 (0.47) | MEN1KMT2APOLBGAACTDSP1 | |
| SCHEMBL14473923 | 0.82 | KDM4E (0.49) | MEN1KMT2APOLBGAAKDM4E | |
| SCHEMBL20281019 | 0.77 | KDM4E (0.46) | MEN1KMT2APOLBGAAKDM4E | |
| Trifluoroacetic Acid SCHEMBL5622861 | 0.76 | KDM4E (0.44) | KDM4EALDH1A1HSD17B10HPGDMAPK1 | |
| Trifluoroacetic Acid SCHEMBL5622863 | 0.76 | KDM4E (0.44) | KDM4EALDH1A1HSD17B10HPGDMAPK1 | |
| SCHEMBL869935 | 0.74 | KDM4E (0.67) | GAAKDM4EALDH1A1HSD17B10HPGD | |
| SCHEMBL15539797 | 0.74 | CTSS (0.43) | MEN1KMT2AKDM4EALDH1A1HPGD | |
| SCHEMBL5429225 | 0.73 | KDM4E (0.67) | GAAKDM4EALDH1A1HSD17B10HPGD | |
| SCHEMBL12919918 | 0.72 | MCL1 (0.61) | MEN1KMT2AGAAKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8357506-B2 | Method of identifying improved conjugates of biologically active compounds | BURNET MICHAEL (DE) | 2013-01-22 | — | — | US | disclosed |
| US-8357506-B2 | Method of identifying improved conjugates of biologically active compounds | BURNET MICHAEL (DE) | 2013-01-22 | — | — | US | disclosed |
| US-7579324-B2 | Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof | C-A-I-R BIOSCIENCES GMBH (DE) | 2009-08-25 | — | — | US | disclosed |
| US-20090093014-A1 | Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof | Burnet, Dr. Michael (DE) | 2009-04-09 | — | — | US | disclosed |
| US-20080145343-A1 | Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof | BURNET, MICHAEL (DE) | 2008-06-19 | — | — | US | disclosed |
| US-20080145343-A1 | Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof | BURNET, MICHAEL (DE) | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080145343-A1 | Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof | CD47, CD14, CD4 | MEN1 2861/4885KMT2A 3242/4885POLB 3431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.